Driven to improve the treatment of
Adamas Pharmaceuticals is dedicated to improving the lives of those affected by central nervous system
(CNS) disorders by optimizing the pharmacokinetic profiles of proven drugs to create novel therapeutics
for use alone and as fixed-dose combination products. The Company has three late-stage investigational
product candidates, including ADS-5102 for treatment of levodopa-induced dyskinesia in Parkinson's disease,
and MDX-8704 and ADS-8704, both fixed-dose combination products for the treatment of Alzheimer's disease.
Adamas plans to advance its product candidates through approval and commercialize products in the United
States through a specialty CNS sales force.